Frankfurt
18.12.25 | 15:29
1,636 Euro
+1,61 % +0,026
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 326 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11. | ADVICENNE: Advicenne has submitted to the US FDA the registration application (NDA) for Sibnayal in dRTA treatment | 3 | Euronext | ||
| 07.10. | ADVICENNE: Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities | 3 | Euronext | ||
| 19.09. | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 390 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08. | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 303 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 28.07. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 424 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07. | Advicenne Reports its H1 2025 Sales | 382 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07. | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 790 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 391 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06. | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 405 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04. | Advicenne 2024 Universal Registration Document Made Available | 299 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 578 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 501 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 491 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 537 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,430 | +0,35 % | Opening Bell: Pfizer, Nike, Tilray, D-Wave, Roku, PayPal, Apple, AMC Robotics | Die US-Börsen haben ihre Verluste zum Wochenauftakt fortgesetzt. Der Dow Jones schloss nahezu unverändert 0,09 Prozent tiefer bei 48.416,56 Punkten, während der Nasdaq Composite deutlicher nachgab und... ► Artikel lesen | |
| ABBVIE | 191,40 | +0,10 % | AbbVie: Top-Pick für Pharma-Anleger? | Die Aktie von AbbVie hat sich 2025 zu einem der auffälligsten Lichtblicke im sonst schwächelnden Pharmasektor entwickelt. Während viele Gesundheitswerte unter dem Druck neuer Technologie-Hypes litten... ► Artikel lesen | |
| HAEMATO | 8,700 | +0,58 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group
16.10.2025... ► Artikel lesen | |
| HALEON | 4,230 | +0,14 % | Haleon: Glasgow Caledonian University to Lead £2.6m UK Doctoral Training Programme to Tackle Global Oral Health Challenges | Glasgow Caledonian University has secured £2.6 million to lead a major new UK-wide doctoral training programme to spearhead research into oral health and dental disease prevention.
This press release... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 165,00 | +1,23 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,705 | +2,63 % | Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program | One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025... ► Artikel lesen | |
| ROYALTY PHARMA | 32,950 | +0,98 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| EISAI | 25,110 | +2,87 % | Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year | TOKYO, Dec 11, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced that it has been selected for the highest-rated "A" List in the fields of Climate... ► Artikel lesen | |
| TG THERAPEUTICS | 26,335 | -0,74 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| DR REDDYS | 11,700 | -3,31 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| BETTERLIFE PHARMA | 0,024 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital | Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused... ► Artikel lesen | |
| KYOWA KIRIN | 13,800 | -1,43 % | Kyowa Kirin meldet geplante Ernennung von Abdul Mullick zum President und Chief Executive Officer - bisheriger CEO Masashi Miyamoto bleibt Chairman | Wechsel in der Unternehmensführung werden nach Abschluss der Hauptversammlung im März 2026 wirksam Bekanntgabe folgt auf ein Jahr mit dualem CEO-/COO-Modell und bedeutet Rückkehr zur Führungsstruktur... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 13,100 | -5,76 % | Oppenheimer raises WAVE Life Sciences stock price target to $32 on WVE-007 data | ||
| IGC PHARMA | 0,282 | 0,00 % | IGC Pharma, Inc.: IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines | POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI)... ► Artikel lesen | |
| IMMUPHARMA | 0,059 | 0,00 % | ImmuPharma shares fall as P140 deal time-frame extended to 2026 |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.